OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

Taipei, Taiwan – 31 January 2013 – A recent paper published by the Academia Sinica explained that a new generation therapeutic cancer vaccine – Globo H-DT (OBI-833) – can effectively target cancer cells and cancer stem cells. These results have been published in the Proceedings of the National Academy of Sciences of the United States […]

This article is password protected.

To view the content, please enter your password in the field below